In vitro Effect of Silver Nanoparticles on *Blastocystis hominis*

This article was published in the following Dove Press journal:
International Journal of Nanomedicine

Mohamed Saad Younis¹
Eman Abd el rahman Abououf¹
Ali El saeed Ali¹
Sara Mohamed Abd elhady²
Rita Maher Wassef²

¹Medical Parasitology Department, Faculty of Medicine, Benha University, Benha, Egypt; ²Medical Parasitology Department, Faculty of Medicine, Helwan University, Cairo, Egypt

Introduction: This study aims to assess the efficacy of silver nanoparticles (Ag Nps) alone and combined with metronidazole (Ag Nps + MTZ) as potential alternative therapeutic agents for *Blastocystis hominis*.

Methods: The parasites were challenged with Ag Nps, Ag Nps + MTZ and MTZ. To assess the efficacy of drugs, counting of viable parasites was done after 1, 2, and 3 hours of adding the drugs.

Results: *Blastocystis hominis* count was reduced by 20.72%, 28.23%, and 18.92% after one hour of adding Ag Nps, Ag Nps + MTZ, and MTZ, respectively. Cysts count was further reduced by 51.49%, 61.61%, and 40.78% after 2 hours and by 71.69%, 79.67%, and 62.65% after 3 hours of adding the drugs in the same order, respectively.

Conclusion: There was a statistically significant difference ($P < 0.05$) in the in vitro growth inhibition of the parasite over the different time intervals when using the tested drugs against the control drug.

Keywords: *Blastocystis hominis*, eosin brilliant cresyl blue stain, metronidazole, silver nanoparticles

Background

B. hominis is a unicellular, obligate, anaerobic protozoan found in the gastrointestinal tract of man; many other vertebrates and invertebrates act as a reservoir host for man.¹ It has a worldwide distribution and is considered one of the most common human protozoa especially in developing countries with a higher prevalence rate (30%–50%) than in developed countries (1.5%–10%).² In Egypt, the prevalence has reached up to 50%.³ It has four main forms which are vacuolar, granular, and amoeboid forms which can be found in culture and cyst form found in the stool. Transmission of the parasite occurs through the feco-oral route especially in people with poor environmental sanitation with frequent exposure to animals and contaminated food.⁴ *B. hominis* may pass unnoticed or might be accompanied by many symptoms like nausea, vomiting, abdominal cramps, fatigue, and diarrhea especially in children and immunocompromised patients.⁵ Various methods are used for diagnosis of *B. hominis* which are microscopic detection of the parasite in fecal specimens, immunodiagnosis, molecular diagnosis and culture on Jones's media. The latter is considered as the gold standard diagnostic method.⁶ Treatment of infected patients is controversial as the symptoms seem to be self-limited in most of the cases; however, it is crucial in case of persistent diarrhea when no other pathogen could be detected in fecal samples with the presence of debilitating

Correspondence: Rita Maher Wassef
Medical Parasitology Department, Faculty of Medicine, Helwan University, 30 Street 276 New Maadi, Cairo, Egypt
Tel +201005782994
Fax +20225193381
Email rita.wassef@med.helwan.edu.eg

symptoms. Although metronidazole is considered the first line of treatment of *B. hominis*,⁷ side effects such as metallic taste, anorexia, nausea, and vomiting may occur. Besides, the regimen of treatment requires a long duration consumption of the drug which may cause headache, vertigo, dizziness, and syncope and sometimes may lead to convulsive seizures, peripheral neuropathy, neutropenia, and leucopenia. Resistance to metronidazole treatment had been also reported since 1976,⁸ thus, there was a great need to develop a new, safer, and more effective alternative drug.

Nanoparticles are new promising emerging drug carriers that proved to be effective in treating many parasitic diseases through overcoming the poor cellular permeability, nonspecific distribution, low bioavailability, and rapid elimination of antiparasitic agents from the body. They can also be used as antimicrobial agents. Among the different types of nanoparticles used as antimicrobial agents, silver nanoparticles (Ag Nps) have proved to have better efficacy against different microorganisms although the exact mechanism of its action is still unresolved.⁹ A proposed mechanism of parasite growth inhibition is by enhancing the function of the immune system; another suggested mechanism is by inducing morphological and structural changes in the parasites¹⁰ and another mechanism is by binding to the cell membrane of the infected cell and causing cellular oxidative stress in microbes.¹¹

Silver nanoparticles are ideal nanocarriers for antiparasitic drug delivery and have been successfully and effectively used to treat several parasitic infections.¹² Nevertheless, their effect on *B. hominis* has not been widely explored yet. Therefore, this study was conducted to detect the effect of silver nanoparticles as a sole agent and as a combination with metronidazole on *B. hominis* in vitro compared to metronidazole.

Methods

Sample Collection and Processing

Stool samples were collected from symptomatic patients attending the outpatient clinic of Theodor Bilharz Research Institute (TBRI) in sterile, disposable clean containers labeled with the patient's name and date of collection. They were examined macroscopically¹³ and microscopically for the presence of *B. hominis* and to exclude the presence of other parasites. Microscopic examination of the samples was done by direct wet smear,¹⁴ iodine stained smear,¹⁵ and formol ether

concentration technique.¹⁶ Positive samples were further cultured in 5 mL of modified Jones' media on the same day of collecting the samples.³ The culture tubes were incubated at 37°C with daily examination for 72 hours. This was done by examining a drop of the supernatant by the low (x10) and high (x40) power fields of a light microscope. Culture tubes were considered negative for *B. hominis* when no parasite growth was detected after 72 h of culture and incubation. Culture tubes were considered suitable for the assessment of the drug when the parasite number/mL exceeded 1×10³ vacuolar forms.¹⁷

Preparation of the Drugs

The synthesis procedure of silver nanoparticles (Ag Nps) and silver nanoparticles loaded with metronidazole (Ag Nps + MTZ) used in the current study was adopted from the procedure developed by Steve and Johnson.¹⁸ The particles were characterized with a transmission electron microscope, and their size distribution had a mean of 40 nm. The surface morphology and size distribution of silver nanoparticles are shown in Figure 1. The concentration used for both drugs was 150 µg/mL. The loading capacity (LC) of nanoparticles was calculated according to the Eq. 1:

$$\%LC = [(A - B)/C] \times 100$$

where "A" is the total amount of MTZ, "B" is the free amount of MTZ and "C" is the weight of nanoparticles.

Commercially available metronidazole (MTZ) (Amrizole® injection for intravenous infusion) 0.5%w/v in 100 mL bottles (500 mg MTZ in 100 mL) was

Figure 1 (A) Transmission electron microscope image showing the surface morphology and image analysis of silver nanoparticles (mean 40 nm). (B) Histogram showing the size distribution of silver nanoparticles.

manufactured and purchased from Amriya for pharmaceutical industries Alexandria, Egypt. It was used as a reference antiprotozoal drug. The drug was protected from light and stored below 30°C. Sterile distilled water was added to the drug until reaching the required concentration of MTZ that was adjusted to 150 µg/mL.

In vitro Anti-*Blastocystis* Activity of Ag Nps, Ag Nps + MTZ and MTZ

Parasite subcultures were done by introducing inoculums from the culture tubes into new sets of culture tubes containing Jones' medium with the tested drugs. Non-treated control cultures of the parasites were also subjected to the same procedure used for the other tested cultures.

Culture tubes were divided into four groups used in triplicate for each drug and the non-treated (control) cultures. Group A was the control group and included culture tubes containing the parasite without treatment; Group B was formed of culture tubes containing the parasite and silver nanoparticles at a concentration of 150 µg/mL; Group C was formed of culture tubes containing the parasite and metronidazole loaded with silver nanoparticles at a concentration of 150 µg/mL while Group D included culture tubes containing the parasite and metronidazole drug at a concentration of 150 µg/mL. The tested cultures were incubated at 37°C and examined after 1, 2, and 3 h. The treatment period of at least 1 h was used in previous standardized studies and had shown that this period is needed to induce the cytotoxic effect in *B. hominis*.¹⁹

Assessment of in vitro Anti-*Blastocystis* Activity of Ag Nps, Ag Nps + MTZ and MTZ

Assessment of the anti-*Blastocystis* activity of the tested drugs was carried out by counting the number of viable cells after 1, 2, and 3 h using eosin-brilliant cresyl blue dye which stained viable cells with green color and nonviable cells with red color.²⁰ Counting the number of viable cells was done in duplication using a Neubauer cell counting chamber under a light microscope. The percentage of growth inhibition of *B. hominis* in the treated cultures to the non-treated cultures was calculated according to the Eq. 2:

$$\text{Growth inhibition (\%)} = \frac{a - b}{a} \times 100$$

where "a" is the mean number of parasites in control cultures and "b" is the mean number of parasites in treated cultures.

Statistical Analysis

Data were coded and entered using the statistical package for the Social Sciences (SPSS) version 26 (IBM Corp., Armonk, NY, USA). Data were summarized using mean and standard deviation for quantitative variables. Comparisons between groups were done using analysis of variance (ANOVA) with multiple comparisons post hoc test.²¹ *P*-values less than 0.05 were considered statistically significant.

Ethical Consideration

This study was performed in line with the principles of the Declaration of Helsinki. The protocol of this study was approved by the scientific research ethics committee of the Faculty of Medicine, Benha University. Patients included in the study were informed verbally about the purpose of the study and the collection of stool samples was performed after obtaining their consent. The informed verbal consent process was approved by TBRI Research Ethics Committee.

Results

The growth of *B. hominis* was inhibited after adding silver nanoparticles, metronidazole loaded with silver nanoparticles, and metronidazole to the culture tubes with all drugs used at a concentration of 150 µg/mL. This inhibition was directly proportional to the time of exposure to the drug (Figures 2–4).

B. hominis cysts count was reduced by 20.72%, 28.23%, and 18.92% after one hour of adding silver nanoparticles, metronidazole loaded with silver nanoparticles, and metronidazole, respectively. The decrease in all groups compared to the control after the first hour was statistically significant (*P*<0.05).

A further significant decrease in the parasitic count was noted in all groups compared to the non-treated control group after 2 and 3 hours of adding the drug (*P* <0.001); the number dropped by 51.49%, 61.61%, and 40.78% after 2 hours with silver nanoparticles, metronidazole loaded with silver nanoparticles and metronidazole, respectively, and dropped again by 71.69%, 79.67%, and 62.65% after 3 hours of adding the drugs in the same orders. The effect of different drugs on the growth of *B. hominis* is illustrated in Table 1. The greatest effect on *B. hominis* was seen when using metronidazole loaded with silver nanoparticles (Figure 5).

Count of *B. hominis* after 1, 2 and 3 hours of adding the silver nanoparticles

Figure 2 Means of the count of *B. hominis* after 1, 2 and 3 hours of adding silver nanoparticles in vitro.

Count of *B. hominis* after 1, 2 and 3 hours of adding metronidazole loaded with silver nanoparticles

Figure 3 Means of the count of *B. hominis* after 1, 2 and 3 hours of adding metronidazole loaded with silver nanoparticles in vitro.

Discussion

Metronidazole is the first line of treatment of *B. hominis*.⁷ However, side effects, treatment failure, and resistance to metronidazole had been reported since 1976 and similar cases of treatment failure were reported later on.⁸ Therefore, a great need to develop newer and safer anti-parasitic agents has emerged.

New approaches such as nanobiotechnology are used nowadays in the treatment of different parasitic infections. The use of nanobiotechnology in the treatment of parasitic diseases is due to the unique properties of nanoparticles as the size of nanomaterials reaches (10–100) nm which is similar to the size of most biological structures, so enhance the penetration of the drug to various tissues of the body.²² A study has suggested the occurrence of interaction between the nanoparticles and the surface of parasites, as

the nanoparticles impair the structure of glycoprotein and lipophosphoglycan molecules which are present on the surface of parasites and are responsible for the infection.²³ They also proposed that the nanoparticles release Reactive Oxygen Species (ROS) which have serious effects on these molecules; thus, they become able to kill the infectious agents leading to termination of the parasitic infection. The authors declared that the main reason for using silver nanoparticles (Ag Nps) in their study was the ability of (Ag Nps) to produce reactive oxygen species (ROS) which have an inhibitory effect on ATP production and DNA replication.²³

The current study was carried out during the period from February 2019 to February 2020; stool samples were collected from patients attending outpatient clinics of Theodor Bilharz Research Institute (T.B.R.I), Giza, Egypt, suffering from gastrointestinal symptoms. By microscopic examination, specimens proved to be infected with *B. hominis* were collected and immediately cultured on Jones' media. Assessment of the effect of silver nanoparticles at a concentration of (150 µg/mL), metronidazole loaded with silver nanoparticles at a concentration of (150 µg/mL) on *Blastocystis hominis* in vitro in comparison to metronidazole at a concentration of (150 µg/mL) was performed after 1 hour, 2 hours, and 3 hours.

The results indicate a significant reduction in the *B. hominis* count by (20.72%, 28.23%, 18.92%) after 1 hour of adding silver nanoparticles, metronidazole loaded with silver nanoparticles, and metronidazole, respectively, with an unvarying concentration of (150 µg/mL).

Moreover, the reduction was (51.49%, 61.61%, 40.78%) after 2 hours and (71.69%, 79.67%, 62.65%) after 3 hours of adding silver nanoparticles, metronidazole loaded with silver nanoparticles, and metronidazole, respectively. All drugs used were at an even concentration of (150 µg/mL).

These results are in agreement with the sole previous study that investigated the inhibitory activity of various concentrations of silver nanoparticles and curcumin nanoparticles (Cur Nps) on *B. hominis* in vitro. The effect of Ag Nps and Cur Nps was significantly higher than that detected for MTZ through different incubation periods. However, it concluded that the effect of the single therapy was better than the combined Cur Nps + Ag Nps.¹⁷ The main difference between this study and our current study is in the incubation period and the time required for drug assessment. In that study, the researchers examined the culture after 72 hours while in our study we examined

Figure 4 Means of the count of *B. hominis* after 1, 2 and 3 hours of adding metronidazole in vitro.

the cultures after 1, 2, and 3 hours. That is because Ag Nps nanoparticles showed anti-parasitic activity on other protozoa like *Entamoeba histolytica* and *Cryptosporidium parvum* with high mortality rates after only 180 min of exposure time to Ag Nps.²⁴ In another study, when MTZ was used in vitro at concentrations of 150 and 250 µg/mL, there was a significant growth inhibition and Apoptotic like changes of *B. hominis* after 1 and 2 hours.²⁵ Similarly, Ag Nps showed significant anti-leishmanial effects by inhibiting the promastigotes proliferation and metabolic activity, with the highest suppressive effect on parasites at a concentration of (200 µg/mL).²⁶ Additionally, according to a previous study, the use of silver nanoparticles between 100 and 200 µg/mL proved to be safe in the experimental animals as all the values of silver detected in different tissues were within the safe range in the experiment.¹⁰ Therefore, the current study was designed to assess the viability of *B. hominis* when challenged with Ag Nps and Ag Nps +MTZ at a concentration of 150 µg/mL for 1, 2, and 3 hours.

Figure 5 Difference of the effect of different drugs on the count of *B. hominis* over the hours.

Silver nanoparticles have been proven to have many inhibitory and cytotoxic effects on many parasites such as *Giardia*, *Toxoplasma*, *Leishmania*, *Plasmodium*, and even insect larvae.²⁷ One study examined the disinfection ability of Ag Nps on *Cryptosporidium parvum* oocysts in vitro and confirmed the results by in vivo study. The researchers detected nearly two orders of magnitude reduction in oocyst shedding in mice fed on Ag Nps treated oocysts when compared with the control group.²⁸ Likewise, another study showed that both silver nanoparticles and silver ions significantly decrease *Cryptosporidium* oocysts viability, in a dose-dependent manner, between concentrations of 0.005 and 500 µg/mL, as assessed by an excystation assay and the shell/sporozoite ratio, the results were statistically significant at 500 and 5000 µg/mL.²⁹

The effects of Ag Nps and Chitosan were studied to evaluate their anti-*Toxoplasma* effects singly or combined as treatment and as prophylaxis in the experimental animals and the results showed that silver nanoparticles used singly or combined with chitosan have anti-toxoplasma

Table 1 Effect of Ag Nps, Ag Nps + MTZ and MTZ on the in vitro Growth of *B. hominis* After Different Incubation Periods, Drugs/Concentration (µg/mL)

Groups (Drugs/Concentration (µg/mL))	Control Group	<i>B. hominis</i> with (Ag Nps 150 µg/mL) Group	<i>B. hominis</i> with Ag Nps + MTZ (150 µg/mL) Group	<i>B. hominis</i> with MTZ (150 µg/mL) Group
(Cells/mL) Mean± SD (1hour)	(22200.00) ± 2107.13	(17600.00) ± 1928.73* (20.72%)	(15933.33) ± 1814.75* (28.23%)	(18000.00) ± 1509.97* (18.92%)
(Cells/mL) Mean±SD (2hours)	(22400.00) ± 2306.51	(10866.67) ± 808.29* (51.49%)	(8600.00) ± 600.00* (61.61%)	(13266.67) ± 702.38* (40.78%)
(Cells/mL) Mean± SD (3hours)	(22133.33) ± 2013.29	(6266.67) ± 808.29* (71.69%)	(4533.33) ± 757.19* (79.67%)	(8266.67) ± 1101.51* (62.65%)

Notes: Values are expressed as mean ± SD and Growth Inhibition (%) from control. *Statistically significant difference compared to infection control group (p<0.05).

potentials. In different tissues, the amount of silver detected was within the safe range. Thus, these nanoparticles proved their effectiveness against the experimental *Toxoplasma* infection.¹⁰ Similarly, another study investigated the effectiveness of Ag Nps on *Leishmania tropica* in both stages amastigote and promastigote, and in comparison to pentostam as a control drug in vitro, it showed the effects of Ag Nps when compared to pentostam at different concentrations.³⁰

The data presented here allow us to confidently propose the use of silver nanoparticles and metronidazole-loaded silver nanoparticles as highly efficient alternative therapy against *B. hominis* infection. Nevertheless, to better understand the mechanism of inhibition and whether these particles induce ultrastructural or immunological changes to the parasite, more studies are still needed. Besides, as cytotoxicity associated with nanotechnology is still raising certain concerns, we recommend conducting further in vivo studies of the combined drug at the current concentration to address this issue.

Data Sharing Statement

All data are available from the corresponding author upon request.

Acknowledgments

The authors deeply appreciate the support given by Prof. Dr Ibrahim Rabee Bayoumi Professor of Immunoparasitology, Immunology and Evaluation of Drug Department, Theodor Bilharz Research Institute (TBRI) for his unlimited effort in the preparation of silver nanoparticles.

Author Contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosure

The authors declared that there were no potential conflicts of interest concerning the research, authorship, and/or publication of this article.

References

1. Yan Y, Su S, Ye J, et al. *Blastocystis* sp. subtype 5: a possibly zoonotic genotype. *Parasitol Res.* 2007;101(6):1527–1532. doi:10.1007/s00436-007-0672-y
2. Eassa SM, Ali HS, El Masry SA, Abd El-fattah AH. *Blastocystis hominis* among immunocompromised and immunocompetent children in Alexandria, Egypt. *Ann Clin Lab Sci.* 2016;4(2):2–92.
3. Hassan MA, Rizk EA, Wassef RM. Modified culture methodology for specific detection of *Blastocystis hominis* in stool samples. *J Egypt Soc Parasitol.* 2016;46(3):541–548. doi:10.12816/0033974
4. Coyle CM, Varughese J, Weiss LM, Tanowitz HB. Blastocystis: to treat or not to treat. *Clin Infect Dis.* 2012;54(1):105–110. doi:10.1093/cid/cir810
5. Sari IP, Benung MR, Wahdini S, Kurniawan A. Diagnosis and identification of blastocystis subtypes in primary school children in Jakarta. *J Trop Pediatr.* 2018;117(8):2585–2590.
6. Elghareeb AS, Younis MS, El Fakahany AF, Nagaty IM, Nagib MM. Laboratory diagnosis of Blastocystis spp. In diarrheic patients. *Trop Parasitol.* 2015;5(1):36–41. doi:10.4103/2229-5070.149919
7. Sekar U, Shanthi M. *Blastocystis*: consensus of treatment and controversies. *Trop Parasitol.* 2013;3(1):35–39. doi:10.4103/2229-5070.113901
8. Rajamanikam A, Kumar S, Samudi C, Kudva M. Exacerbated symptoms in *Blastocystis* sp.-infected patients treated with metronidazole: two case studies. *J Trop Pediatr.* 2018;64(3).
9. Ferdous Z, Nemmar A. Health impact of silver nanoparticles: a review of the biodistribution and toxicity following various routes of exposure. *Int J Mol Sci.* 2020;21(7):2375. doi:10.3390/ijms21072375
10. Gaafar MR, Mady RF, Diab RG, Shalaby TI. Chitosan and silver nanoparticles: promising anti-toxoplasma agents. *Exp Parasitol.* 2014;143:30–38. doi:10.1016/j.exppara.2014.05.005
11. Abaza SM. Applications of nanomedicine in parasitic diseases. *Parasitol United J.* 2016;9:1–6. doi:10.4103/1687-7942.192997
12. Sun Y, Chen D, Pan Y, et al. Nanoparticles for antiparasitic drug delivery. *Drug Deliv.* 2019;26(1):1206–1221. PMID: 31746243; PMCID: PMC6882479. doi:10.1080/10717544.2019.1692968
13. Johnstone N. Macroscopic examination of the feces. *J Osteopath (Kirksvill).* 1950;57(10):20–21.
14. Cheesbrough M. *Medical Laboratory Manual for Tropical Countries*. Britain: Butterworth Heinemann Ltd.; 1991:175–185.
15. King M. *A Medical Laboratory for Developing Countries*. Vol. 15. ELBS, Oxford University Press; 1975:45–55.
16. Cheesbrough M. *Medical Laboratory Manual for Tropical Countries*. *Tropical Health Technology*. Vol. 88. Butterworth-Heinemann; 1987:365–389.
17. Ahmed MAF, Ismail KA, Ahmed SAEG, Ibrahim AN, Gohar YM. In vitro activity of curcumin and silver nanoparticles against *Blastocystis hominis*. *Infect Dis Clin Pract.* 2015;23:135–140. doi:10.1097/IPC.0000000000000242
18. Solomon SD, Bahadory M, Jeyarajasingam AV, et al. Synthesis and study of silver nanoparticles. *J Chem Educ.* 2007;84(2):322–325. doi:10.1021/ed084p322
19. Stenzel DJ, Boreham PFL. *Blastocystis hominis* revisited. *Clin Microbiol Rev.* 1996;9:563–584. doi:10.1128/CMR.9.4.563
20. Yang LQ, Singh M, Yap EH, et al. In vitro response of *Blastocystis hominis* against traditional Chinese medicine. *J Ethnopharmacol.* 1996;55:35–42. doi:10.1016/S0378-8741(96)01471-7

21. Chan YH. Biostatistics102: quantitative data – parametric & non-parametric tests. *Singapore Med J.* 2003;44(8):391–396.
22. Norouzi R. A review on most nanoparticles applied against parasitic infections. *J Biol Today's World.* 2017;6(10):196–203.
23. Choi O, Hu Z. Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. *Environ Sci Technol.* 2008;42(12):4583–4588. doi:10.1021/es703238h
24. Saad H, Soliman MI, Azzam AM, Mostafa B. Antiparasitic activity of silver and copper oxide nanoparticles against entamoeba histolytica and cryptosporidium parvum cysts. *J Egypt Soc Parasitol.* 2015;45(3):593–602. doi:10.12816/0017920
25. El-sayed SH, Amer N, Ismai S, et al. In vitro and in vivo anti-blastocystis efficacy of olive leaf extract and bee pollen compound. *Res J Parasitol.* 2017;12:33–44. doi:10.3923/jp.2017.33.44
26. Allahverdiyev AM, Kon KV, Abamor ES, Bagirova M, Rafailovich M. Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. *Expert Rev Anti Infect Ther.* 2011;9(11):1035–1052. doi:10.1586/eri.11.121
27. Elmi T, Gholami S, Fakhar M, Azizi F. A review on the use of nanoparticles in the treatment of parasitic infections. *J Mazand Univ Med Sci.* 2013;23(102):126–133.
28. Su YH, Tsegaye M, Varhue W, et al. Quantitative dielectrophoretic tracking for characterization and separation of persistent subpopulations of *Cryptosporidium parvum*. *Analyst.* 2014;139:66–73. doi:10.1039/C3AN01810E
29. Cameron P, Gaiser BK, Bhandari B, et al. Silver nanoparticles decrease the viability of cryptosporidium parvum oocysts. *Appl Environ Microbiol.* 2015;82(2):431–437.
30. Gharby MA, AL-Qadhi BN, Jaafar SM. Evaluation of silver nanoparticles (Ag NPs) activity against the viability of *Leishmania tropica* promastigotes and amastigotes in vitro. *Iraqi J Sci.* 2017;58(1):13–21.

International Journal of Nanomedicine

Dovepress

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,

Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-nanomedicine-journal>